Innovent Appears on Track to Meet 2027 Revenue Target -- Market Talk

Dow Jones

Yesterday

0518 GMT - Innovent is on track to become a leading biopharmaceutical company in China, Deutsche Bank analyst Cyrus Ng says in a note. Ng notes the management is confident in achieving its 2027 revenue target of CNY 20 billion. He adds that the company appears on course to reach its 2030 target of having more than five pipeline assets entering multi-regional Phase III trials. A key concern is the average sales pressures for its weight-loss drug, Mazdutide, he adds. "We like the short term business growth potential of Innovent from its current product portfolio and the mid-term global expansion plan," says Ng. DB raises its target to HK$110 from HK$107 for its shares, which are 4.6% up at HK$89.35. (jason.chau@wsj.com)

(END) Dow Jones Newswires

February 10, 2026 00:18 ET (05:18 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610769727"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610769727\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610769727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 13:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610769727","market":"nz","top_or_hot":-1,"title":"Innovent Appears on Track to Meet 2027 Revenue Target -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0518 GMT - Innovent is on track to become a leading biopharmaceutical company in China, Deutsche Bank analyst Cyrus Ng says in a note. Ng notes the management is confident in achieving its 2027 revenue target of CNY 20 billion. He adds that the company appears on course to reach its 2030 target of having more than five pipeline assets entering multi-regional Phase III trials. A key concern is the average sales pressures for its weight-loss drug, Mazdutide, he adds. \"We like the short term business growth potential of Innovent from its current product portfolio and the mid-term global expansion plan,\" says Ng. DB raises its target to HK$110 from HK$107 for its shares, which are 4.6% up at HK$89.35. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 00:18 ET (05:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Appears on Track to Meet 2027 Revenue Target -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Appears on Track to Meet 2027 Revenue Target -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-10 13:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0518 GMT - Innovent is on track to become a leading biopharmaceutical company in China, Deutsche Bank analyst Cyrus Ng says in a note. Ng notes the management is confident in achieving its 2027 revenue target of CNY 20 billion. He adds that the company appears on course to reach its 2030 target of having more than five pipeline assets entering multi-regional Phase III trials. A key concern is the average sales pressures for its weight-loss drug, Mazdutide, he adds. \"We like the short term business growth potential of Innovent from its current product portfolio and the mid-term global expansion plan,\" says Ng. DB raises its target to HK$110 from HK$107 for its shares, which are 4.6% up at HK$89.35. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 00:18 ET (05:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242644610.SGD","symbol_name":"Fidelity China Innovation A-ACC-SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610769727","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610769727","pubTimestamp":1770700680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0518 GMT - Innovent is on track to become a leading biopharmaceutical company in China, Deutsche Bank analyst Cyrus Ng says in a note. Ng notes the management is confident in achieving its 2027 revenue target of CNY 20 billion. He adds that the company appears on course to reach its 2030 target of having more than five pipeline assets entering multi-regional Phase III trials. A key concern is the average sales pressures for its weight-loss drug, Mazdutide, he adds. \"We like the short term business growth potential of Innovent from its current product portfolio and the mid-term global expansion plan,\" says Ng. DB raises its target to HK$110 from HK$107 for its shares, which are 4.6% up at HK$89.35. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1589":"北水核心资产","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1583":"高瓴概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","01801":"信达生物","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC"},"translate_title":"信达生物似乎有望实现2027年收入目标——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9},"content_text":"0518 GMT - Innovent is on track to become a leading biopharmaceutical company in China, Deutsche Bank analyst Cyrus Ng says in a note. Ng notes the management is confident in achieving its 2027 revenue target of CNY 20 billion. He adds that the company appears on course to reach its 2030 target of having more than five pipeline assets entering multi-regional Phase III trials. A key concern is the average sales pressures for its weight-loss drug, Mazdutide, he adds. \"We like the short term business growth potential of Innovent from its current product portfolio and the mid-term global expansion plan,\" says Ng. DB raises its target to HK$110 from HK$107 for its shares, which are 4.6% up at HK$89.35. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 00:18 ET (05:18 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}